180 Life Sciences Corp. (ATNF)
Dopo ore: 04:58PM EST
| Chiusura precedente | 4,46 |
| Aperto | 4,46 |
| Denaro | 5,56 x 1400 |
| Lettera | 5,55 x 1200 |
| Min-Max giorno | 4,27 - 5,56 |
| Intervallo di 52 settimane | 2,18 - 13,05 |
| Volume | 2.288.024 |
| Media Volume | 803.433 |
| Capitalizzazione | 184,029M |
| Beta (5 anni mensile) | -0,23 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,07 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,00 |
- GlobeNewswire
180 Life Sciences Corp. Expands Patent Portfolio
New IP Relates to a Method for Treating Chronic Pain or Associated Conditions/Symptoms with Novel Compositions Including Certain Phenyl Substituted Cyclohexenyl Compounds Related to Cannabidiol (CBD)PALO ALTO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced th
- GlobeNewswire
180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium
‘Re-purposing anti-TNF for Dupuytren’s Disease’ Being Presented Wednesday, December 1, 2021, at 3pm ESTPALO ALTO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences,
- GlobeNewswire
180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer
Highly Accomplished Strategy, Corporate/Business Development, Finance and Operations Executive With 20 Years of Biopharma ExperiencePALO ALTO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/
